Expression of P16 and PDGFR-beta in gastric adenocarcinoma.
OBJECTIVE
To detect immunohistochemistry expression of p16 and PDGFR-beta on gastric adenocarcinoma.


METHODS
Thirty six patients submitted to surgery for gastric adenocarcinoma between 1998 and 2002 at Santa Casa de Porto Alegre Hospital have been studied. Variables investigated were: age, gender, tumour size and localization, number of dissected and metastatic nodes, histological type, surgical resection extension and pathological staging.


RESULTS
No expression of PDGFR-beta has been detected on surgical specimens. Concerning to p16, loss of expression lower than 10% and 1% has been detected respectively on 89% and 79% of the specimens studied.


CONCLUSIONS
There has been no correlation among p16 loss and variables studied.
Pinto
Rodrigo Pozza
RP
School of Medicine, UFRGS-RS- BR. rppinto@terra.com.br
Lima
Fernando Krebs Cirne
FK
Kulkzynski
Jane M U
JM
Moreira
Luis Fernando
LF
D000230:Adenocarcinoma / Q000378:metabolism*; D000368:Aged; D019941:Cyclin-Dependent Kinase Inhibitor p16; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000096:biosynthesis*; D013274:Stomach Neoplasms / Q000378:metabolism*
C000614131:CDKN2A protein, human; D019941:Cyclin-Dependent Kinase Inhibitor p16; D009363:Neoplasm Proteins; D020797:Receptor, Platelet-Derived Growth Factor beta